PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC

IMpower010 (NCT02486718) was the first Phase III immunotherapy study to show a statistically significant disease-free survival (DFS) benefit with adjuvant atezolizumab vs best supportive care (BSC) in resected NSCLC following platinum-based chemotherapy (Felip et al. Lancet 2021). Based on these findings, atezolizumab was approved as adjuvant treatment after resection and platinum-based chemotherapy in patients with programmed death-ligand 1 (PD-L1) tumour cell (TC) ≥1% stage II-IIIA NSCLC in the US, China, and other countries; and in PD-L1 TC ≥50% stage II-IIIA NSCLC in the EU and other countries The key secondary OS endpoint was not mature at the IMpower010 DFS interim analysis (IA) but is of considerable clinical interest in this curative setting.